Clinical Trial Update: Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of AVTX-801 (D-galactose) for Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phosphoglucomutase 1-related Congenital Disorder of Glycosylation

Drugs mentioned

• AVTX-801 (D-galactose)

Snippet

Sponsor: Eva Morava-Kozicz | Conditions: PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation | Phase 2 | Status: NOT_YET_RECRUITING